Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This case report describes a patient who experienced proton-induced alopecia after proton therapy for a frontal meningioma, which was effectively treated with topical minoxidil, resulting in full hair regrowth after 4 months.

This study observed that the expression of hsa-miR-193a-5p was significantly higher in alopecia areata patients compared to healthy controls, suggesting its role in influencing disease progression through impact on specific signaling pathways and highlighting its potential as a therapeutic target.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

According to this study, Ireland’s current eligibility criteria for financial assistance on hair replacement products exclude many individuals with alopecia, such as children with non-chemotherapy-induced alopecia, and expanding support could align the country with more inclusive international policies.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that spanlastic gel loaded with thymoquinone and ascorbic acid improved skin deposition and tyrosinase inhibition, suggesting potential as a treatment for hyperpigmentation.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study found that the MIRA technique, using ultrasound-guided needle adjustments, improved cellulite treatment outcomes compared to standard methods in women with stage 3 cellulite, evidenced by greater reductions in adipose thickness and other skin irregularities, along with higher patient satisfaction.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This review highlights icariin’s potential to regulate macrophages in varying conditions, discussing its effects on macrophage polarization, metabolism, and disease mechanisms, and noting the development of delivery systems to enhance its therapeutic impact.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This study observed that infrared light therapy, alone or combined with hyaluronic acid and calcium hydroxylapatite, effectively improved skin laxity with high patient satisfaction and minimal adverse effects among women aged 37 to 68.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.